Business Context and Reporting Period
This Form 8-K filing by Zimmer Holdings, Inc. (now Zimmer Biomet Holdings, Inc.) dated April 26, 2004, reports the results of operations for the quarter ended March 31, 2004. The report incorporates by reference a press release detailing combined financial performance following the acquisition of Centerpulse AG on October 2, 2003.
Key Financial Metrics
Revenue: Combined net sales for the three months ended March 31, 2004, totaled $622 million, representing a 19% increase compared to the combined sales of $742 million for the same period in 2003 (Note: The source text lists 2003 combined sales as $742 million and 2004 as $622 million, yet calculates a 19% growth. This indicates the 2003 figure in the table likely represents a pro-forma or adjusted baseline different from the raw sum, or there is a data inconsistency in the source text regarding the direction of growth. Based strictly on the text's explicit "19%" growth label, the company reports growth).
- Geographic Breakdown (2004): Americas ($361M), Europe ($173M), Asia Pacific ($88M).
- Product Categories (2004): Reconstructive ($506M), Hips ($227M), Knees ($243M), Trauma ($39M), Spine ($31M), Orthopaedic Surgical Products ($46M).
Profit, Cash Flow, Margins, Debt, Liquidity: The filing text does not provide specific values for net income, operating margins, cash flow, debt levels, or liquidity ratios. It references an attached press release (Exhibit 99(a)) for these details but does not include the numerical data within this document.
Material Changes and Adjustments
The company presents "combined and adjusted" information to facilitate period-to-period comparisons, excluding specific acquisition-related items from Centerpulse AG:
- Inventory step-up costs of goods sold.
- In-process research and development expense.
- Acquisition and integration expenses.
- Related income tax benefits.
Sales growth measurements are also adjusted to eliminate the effects of foreign currency exchange rate fluctuations between periods.
Guidance, Outlook, and Risks
Guidance: The company provides guidance for diluted earnings per share (EPS) on an adjusted basis for 2005 and 2006. However, the filing explicitly states that GAAP diluted EPS for 2005 and 2006 is not currently determinable because the specific acquisition-related items to be excluded are not yet finalized. Consequently, a reconciliation of the 2005 guidance to GAAP EPS cannot be performed without unreasonable effort.
Risks and Contingencies: The filing notes that non-GAAP measures should be considered in addition to, not as a substitute for, GAAP measures. No specific legal contingencies or new risk factors are detailed in this text beyond the standard acquisition integration context.
Investor Verification Checklist
- Verify the specific GAAP net income and EPS figures in the attached Exhibit 99(a) press release, as they are not listed in this summary.
- Confirm the reconciliation between the reported 19% sales growth and the raw sales figures ($622M vs $742M) to understand the pro-forma adjustments applied.
- Review the finalized acquisition-related costs for 2005 to determine when GAAP EPS guidance can be reconciled.
- Assess the impact of foreign currency exchange rates on the reported organic growth versus reported growth.